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de Llobregat, Barcelona, Spain; 34University Hospital Limerick, Limerick, Ireland; 35Department of Respiratory Medicine, Mater
Misericordiae University Hospital, Dublin, Ireland; 36Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy; 37UCL
Respiratory, University College London and ILD Service, University College London Hospitals NHS Foundation Trust, London,
United Kingdom; 38Imperial Healthcare NHS Trust, St. Mary’s Hospital, The Bays, London, United Kingdom; 39Laboratory of Biochemistry
and Genetics, Pneumology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
(Received in original form July 15, 2020; accepted in final form October 2, 2020 )
This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/
licenses/by/4.0/).
Correspondence and requests for reprints should be addressed to R. Gisli Jenkins, M.D., Ph.D., National Institute for Health Research Biomedical Research
Centre Nottingham Respiratory Research Unit, University of Nottingham, Hucknall Road, Nottingham NG14 7FW, UK. E-mail: gisli.jenkins@nottingham.ac.uk.
This article has a related editorial.
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org.
Am J Respir Crit Care Med Vol 202, Iss 12, pp 1656–1665, Dec 15, 2020
Copyright © 2020 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.202007-2794OC on October 2, 2020
Internet address: www.atsjournals.org
1656 American Journal of Respiratory and Critical Care Medicine Volume 202 Number 12 | December 15 2020
 
40University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom; 41Royal United
Hospitals Bath NHS Foundation Trust, Bath, United Kingdom; 42Institute of Lung Health, Interstitial Lung Disease Unit, Glenfield Hospital,
Leicester, United Kingdom; 43NIHR Biomedical Research Centre, Respiratory Research Unit, University of Nottingham, Nottingham,
United Kingdom; 44Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; 45Intensive Care Unit, Royal Infirmary
Edinburgh, Edinburgh, United Kingdom; 46NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of
Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom;
and 47Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, United Kingdom
ORCID IDs: 0000-0002-5456-6080 (D.T.); 0000-0001-5258-793X (J.K.B.); 0000-0002-7220-2555 (P.J.M.O.).
Abstract
Rationale: The impact of coronavirus disease (COVID-19) on
patients with interstitial lung disease (ILD) has not been established.
Objectives:To assess outcomes in patientswith ILDhospitalized for
COVID-19 versus those without ILD in a contemporaneous age-,
sex-, and comorbidity-matched population.
Methods:An internationalmulticenter audit of patients with a prior
diagnosis of ILD admitted to the hospital with COVID-19 between
March 1 and May 1, 2020, was undertaken and compared with
patients without ILD, obtained from the ISARIC4C (International
Severe Acute Respiratory and Emerging Infection Consortium
Coronavirus Clinical Characterisation Consortium) cohort,
admitted with COVID-19 over the same period. The primary
outcome was survival. Secondary analysis distinguished idiopathic
pulmonaryfibrosis fromnon–idiopathic pulmonary fibrosis ILD and
used lung function to determine the greatest risks of death.
Measurements and Main Results: Data from 349 patients with
ILD across Europe were included, of whom 161 were admitted to the
hospital with laboratory or clinical evidence of COVID-19 and
eligible for propensity score matching. Overall mortality was 49%
(79/161) in patients with ILD with COVID-19. After matching,
patients with ILD with COVID-19 had significantly poorer survival
(hazard ratio [HR], 1.60; confidence interval, 1.17–2.18; P= 0.003)
than age-, sex-, and comorbidity-matched controls without ILD.
Patients with an FVC of,80% had an increased risk of death versus
patients with FVC>80% (HR, 1.72; 1.05–2.83). Furthermore, obese
patientswith ILDhad an elevated risk of death (HR, 2.27; 1.3923.71).
Conclusions: Patients with ILD are at increased risk of death from
COVID-19, particularly those with poor lung function and obesity.
Stringent precautions should be taken to avoidCOVID-19 in patients
with ILD.
Keywords: COVID-19; idiopathic pulmonary fibrosis; interstitial
lung disease; obesity; lung function
At a Glance Commentary
Scientific Knowledge on the Subject: The outcome of
patients with interstitial lung disease (ILD) admitted to the
hospital with coronavirus disease (COVID-19) infection and
the risk factors associated with severe COVID-19 are not
known.
What This Study Adds to the Field: The study demonstrates
that patients with ILD are at higher risk of death after COVID-
19 than matched patients without ILD, and the risk factors for
death include male sex, an FVC ,80% predicted, and obesity.
Interstitial lung diseases (ILDs) represent
a group of fibroinflammatory diseases
affecting the alveolar interstitium of the
lung. ILDs are characterized by alveolar
damage and interstitial thickening and,
if left untreated, lead to remorseless
progression of breathlessness, cough, and,
ultimately, death from respiratory failure.
The prevalence of ILDs in Europe is just
under 1 per 1,000 people, with an annual
incidence of approximately 20 per 100,000
people (1). The commonest ILD is
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sarcoidosis, but one of the most severe ILDs
is idiopathic pulmonary fibrosis (IPF), a
high incidence of which is found in the UK
(12 per 100,000) (2, 3). IPF tends to affect
older people, with a mean age at diagnosis
of 72 years. Men are more often affected
than women. Furthermore, IPF is
associated with diabetes mellitus type 2,
hypertension, and ischemic heart disease (4,
5). People suffering from other ILDs (non-
IPF ILD) tend to be younger, with a higher
proportion of female sufferers, and often
receive immunosuppressive therapy.
All ILDs, most notably IPF, are
characterized by acute exacerbations, which
have a particularly high mortality rate
ranging from 35% to 70% (6). The precise
cause of acute exacerbations is unknown,
but they have been associated with thoracic
surgical procedures and viral infections (6).
Furthermore, an acute exacerbation is
associated with the development of acute
respiratory distress syndrome (ARDS),
which carries a high mortality and
morbidity. However, there is no consensus
on treatment of ARDS in this group of
patients, given that mechanical ventilation
is the cornerstone of supportive therapy in
patients without ILD (7).
Infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)
may lead to coronavirus disease (COVID-
19), characterized by a severe viral
pneumonia and ARDS in approximately
20% of patients admitted to the hospital (8).
Patients most at risk of severe COVID-19
include elderly males with comorbidities
including diabetes mellitus type 2,
hypertension, and ischemic heart disease (9,
10), which are shared by patients with ILD,
most notably IPF (5). To understand the
risk to patients with ILD hospitalized with
COVID-19 and therefore the potential
benefits of self-isolation during the
pandemic, we undertook an international
multicenter analysis of patients admitted to
the hospital between March 1 and May 1,
2020, with COVID-19. We compared
outcomes of patients with ILD with age-,
sex-, and comorbidity-matched controls
admitted with COVID-19 but without
ILD, from a prospective UK cohort, the
ISARIC4C CCP-UK (International Severe
Acute Respiratory and Emerging Infection
Consortium Coronavirus Clinical
Characterisation Protocol UK).
Some of the results of these studies have





Physicians admitting patients with ILD
throughout Europe were contacted through
research networks, e-mail contacts, and social
media and asked to identify all patients with a
preexisting diagnosis of ILD admitted to the
hospital between March 1 and May 1, 2020,
during the first peak of the COVID-19
pandemic. Participating centers included
tertiary ILD centers from Denmark,
Germany, Italy, the Republic of Ireland,
Spain, and the UK and secondary care
hospitals from the Republic of Ireland and the
UK to obtain as representative a European
ILD population as possible. Deidentified,
unlinked data from individuals were included
in the audit. Each contributing site was asked
to identify individuals admitted to their local
hospital. As SARS-CoV-2 was an emerging
virus at the start of the pandemic and PCR
testing has a high false-negative rate, we
defined the diagnosis of COVID-19 based on
a SARS-CoV-2–positive PCR swab and/or
clinicoradiological diagnosis. Audit data were
unified with the ISARIC4C CCP-UK
database, with separate categorization of
individuals who reported an existing chronic
pulmonary disease. The ISARIC4C CCP-UK
database is a prospective cohort study
enrolling patients across the UK admitted to
the hospital with COVID-19. Patients
admitted were identified by local
investigators and followed up prospectively
by clinical research staff. Detailed data on
comorbidities, treatments received, and





Patients with ILD with
outcome data
n=349
Patients with ILD with
COVID-19 diagnosis
n=185



















Figure 1. Audit flow diagram showing patients recruited and flow to matching. COVID-19=
coronavirus disease; ILD= interstitial lung disease; ISARIC4C= International Severe Acute
Respiratory and Emerging Infection Consortium Coronavirus Clinical Characterisation Consortium.
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Data on the presence of chronic lung
disease and asthma and prescription data
were collected for the comparator group.
Based on these variables, patients with no
previous respiratory disease were selected to
most accurately estimate the change in
hazard for patients with ILD. Significant
comorbidities of diabetes (type 1 or type 2),
hypertension, chronic heart disease, and
malignancy, as well as immunomodulatory
therapies, were recorded in both ILD audit
data and the ISARIC database.
Outcomes
The primary outcome was in-hospital
mortality, and other recorded outcomes
were whether the patient was discharged
or remained hospitalized at the date of
censoring (May 1, 2020). Secondary
outcomes included whether patients were
ventilated or received continuous positive
airway pressure, other noninvasive
ventilation, or high-flow oxygen and
were described as “enhanced respiratory
support.” Length of stay was recorded
at date of death, discharge, or date of
censoring. All outcomes were recorded on
a standardized case report form and
entered without any identifiers directly
onto a secure REDcap database.
Ethics and Consent
All data were entered by the local clinical
care team in anonymized fashion without
linkage to any patient identifiers in line with
national and local audit guidance. In the UK,
Health Research Authority guidance was
followed (https://www.hra.nhs.uk/covid-
19-research/guidance-using-patient-data/),
and ethical approval was not required.
Similar regulations applied in Denmark,
Italy, and the Republic of Ireland.
ISARIC4C CCP-UK received ethical
approval from the South Central -
Oxford C Research Ethics Committee in
England (Ref: 13/SC/0149), and by the
Scotland A Research Ethics Committee
(Ref: 20/SS/0028). Data from Spain
were collected under the approval for
observational studies (Ref: UIC-IBU-2020-
03 and PR217/20). Data from Germany
were collected under approval from ethics
committee of the Medical faculty of the
University of Heidelberg (Ref: S-186/2020).
Statistical Analysis
Summary statistics are presented as
frequencies and percentages for
categorical data and mean (SD) for
normally distributed continuous data.
Where continuous data were not normally
distributed, the median (interquartile range
[IQR]) was used. Differences in categorical
data were compared using the chi-square
test or Fisher’s exact test when expected
counts were below 5 in any group. For
continuous normally distributed two-group
data, we compared differences using
Welch’s t test or Mann-Whitney U if data
were not normally distributed. For multiple
group comparisons of continuous data, we
used Kruskal-Wallis tests. Data from the
ILD data set were matched in a 1:2 ratio
with patients who did not have ILD from
the ISARIC4C CCP-UK data set using a
nearest neighbor propensity score matching
algorithm. Patients in ISARIC4C CCP-UK
with ILD were excluded to avoid double
counting. We matched on confounders
known to affect outcomes from COVID-19
disease including age, sex, diabetes, chronic
cardiac disease, cancer, hypertension, and
renal disease. Unmatched and matched
populations were compared using
standardized mean differences, plots, and
summary statistics. For survival analyses,
time was taken as admission to death (in-
hospital survival) using length of stay where
date was not available. Discharge from
hospital was considered an absorbing state
(once discharged, patients were considered
no longer at risk of death). Discharged
patients were not censored and included
in the risk set until the end of follow-up;
thus, discharge did not compete with death.
We generated subclasses based on the
propensity score distance and included
these as terms within Cox proportional
hazards models, where estimates are
presented as hazard ratios (HRs), alongside
the corresponding 95% confidence interval
(CI) (11). Data were analyzed using R
version 3.6.3 (R Foundation for Statistical




Between March 1 and May 1, 2020, 349
patients with ILD were admitted to 37
hospitals throughout the UK and Europe
(see Table E1 in the online supplement).
Table 1. Patient Characteristics by ILD
Total (n) No ILD ILD P Value
Total 483 322 (66.7) 161 (33.3) —
Age, yr, mean (SD) 483 72.6 (13.4) 73.2 (11.5) 0.639*
Age categories 483
,50 yr 10 (3.1) 5 (3.1) 1.000
50–69 yr 112 (34.8) 56 (34.8) —
70–79 yr 96 (29.8) 48 (29.8) —
>80 yr 104 (32.3) 52 (32.3) —
Sex at birth, M 483 220 (68.3) 110 (68.3) 1.000
ILD
Chronic hypersensitivity pneumonitis 0 (0.0) 14 (8.7) —
Connective tissue disease–related ILD 0 (0.0) 13 (8.1) —
Idiopathic pulmonary fibrosis 0 (0.0) 68 (42.2) —
Other 0 (0.0) 47 (29.2) —
Rheumatoid-related ILD 0 (0.0) 10 (6.2) —
Sarcoidosis 0 (0.0) 9 (5.6) —
Chronic cardiac disease, yes 483 92 (28.6) 46 (28.6) 1.000
Diabetes, yes 483 98 (30.4) 49 (30.4) 1.000
Malignant neoplasm, yes 483 56 (17.4) 28 (17.4) 1.000
Obesity 419
Yes 23 (7.1) 45 (28.0) ,0.001
Missing 32 (9.9) 32 (19.9) —
Hypertension, yes 483 148 (46.0) 74 (46.0) 1.000
Chronic kidney disease, yes 483 16 (5.0) 8 (5.0) 1.000
Pirfenidone, yes 483 0 (0.0) 7 (4.3) —
Nintedanib, yes 483 0 (0.0) 13 (8.1) —
Corticosteroids, yes 483 28 (8.7) 45 (28.0) ,0.001
Definition of abbreviation: ILD= interstitial lung disease.
Data are shown as n (%) unless noted otherwise. All tests are chi-square except where noted.
*Welch’s two-sample t test used.
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A total of 185 patients with ILD had a
diagnosis of COVID-19, and 161 were
suitable for propensity score matching
(Figure 1). The majority of these 161
patients (114) had a positive SARS-CoV-2
PCR test, and only 47 were diagnosed
clinically. Of these, 110 (68%) were male
and the mean age was 73.2 (11.5) years. The
most common ILD was IPF, with 68 (42%)
patients admitted to the hospital (Table 1).
During the same period, 164 patients with
ILD were admitted with an alternative non-
COVID diagnosis, of whom 69 (42.1%)
had IPF. Overall, the in-hospital mortality
for patients with ILD and COVID-19
was 49% (79/161) compared with 17%
(28/164) for patients with ILD admitted
for other reasons.
Effect of ILD on Outcome from
COVID-19
After propensity score matching, 161
patients with ILD were compared with 322
patients admitted to the hospital between
March 1 and May 1, 2020, but without ILD
or other chronic lung disease (Table 1).
There was significantly higher mortality in
patients with ILD than in those without
ILD (49% [79/161] vs. 35% [114/322];
P= 0.013), and ILD was associated with an
increased risk of death in a matched
adjusted analysis (HR, 1.60; 95% CI,
1.17–2.18; P= 0.003). There was
significantly higher mortality in patients
with ILD than in those without ILD
(Figure 2), which was greatest in men and
increased with age, which persisted for men
after adjusting for age and comorbidity
(adjusted HR, 1.98; 95% CI, 1.14–3.43;
P= 0.015). Survival was significantly poorer
in patients with IPF (HR, 1.74; 95% CI,
1.16–2.60; P= 0.007), and poorer survival
was also seen in non-IPF ILD (HR, 1.50;
95% CI, 1.02–2.21; P= 0.040; Figure 3A)
than in matched patients without ILD. Of
patients with non-IPF ILD, those with
chronic hypersensitivity pneumonitis and
rheumatoid ILD had the highest mortality
(50% [7/14] and 40% [4/10], respectively),
whereas those with sarcoidosis and
connective tissue disease (excluding
rheumatoid)–related ILD had the lowest
observed mortality (33% [3/9] and 23%
[3/13], respectively). Overall, median length
of stay in those who were still alive was not
substantially different between patients
without ILD (9 [IQR, 11] d) and those with
non-IPF ILD (10 [IQR, 8] d) and IPF
(10 [IQR, 8] d) (P= 0.725) (Table 2).
Predictors of Outcome from
COVID-19
Obesity has been previously described to
increase the risk of death from COVID-19.
After obesity was included in the propensity
score matching (129/161 patients with ILD
with data available, matched to 260 patients
without ILD), being obese and having
ILD was significantly associated with an
increased hazard of death from COVID-19
(adjusted HR, 2.27; 95% CI, 1.39–3.71;
P= 0.001; Figure 3B), which was greater
than the effect of obesity in patients
without ILD.
To determine whether patients with
more severe ILD had a greater risk of
mortality with COVID-19, the last available
lung function results before hospital
admission were analyzed. For all patients
with ILD, the mean FVC in patients
surviving COVID-19 was 82.2% predicted
compared with 76.8% predicted in patients
who died (P= 0.121). Similarly, the mean
DLCO was 56.4% predicted in survivors
compared with 49.6% in patients dying
with COVID-19 (P= 0.072; Table 3). When
the FVC was dichotomized using the 80%
predicted threshold between mild and
moderate ILD, in line with UK prescribing
policy for antifibrotic medication, survival
was significantly poorer in patients with
moderate or severe ILD (HR, 1.72; 95% CI,
1.05–2.83) than in patients with mild
disease (Figure 3C).
Ventilatory Support for Patients with
ILD with COVID-19
Most patients with ILD (84%; 135/161) did
not receive enhanced respiratory support,
which was similar to matched patients
without ILD (79%; 254/322; Table 2).
Significantly more patients who survived
did not receive enhanced respiratory
support (93%; 76/82) compared with those
who died (75%; 59/79; P= 0.015). Of the 26
patients receiving enhanced respiratory
support, 77% (20) died, including 83% (5/6)
of matched patients with ILD receiving
ventilation (Table 4).
In-hospital mortality rate in patients with COVID-19

































Figure 2. (A) In-hospital mortality with 95% confidence intervals for female patients with interstitial
lung disease (ILD) hospitalized with coronavirus disease (COVID-19) stratified by age compared with
those without ILD. (B) In-hospital mortality with 95% confidence intervals for male patients with ILD
hospitalized with COVID-19 stratified by age compared with those without ILD.
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Effect of Antifibrotic and
Immunosuppressive Therapy on
Outcome from COVID-19
In patients with ILDs, 106 were taking no
immunosuppressants or antifibrotics, of
whom 50% died (53/106; Table 5). Almost
one-third of patients with IPF (20/68)
were receiving antifibrotic therapy at the
time of admission. Seven patients were
receiving pirfenidone and 13 were receiving
nintedanib. Of those receiving antifibrotic
therapy, 50% (10/20) died. Where
immunosuppressants were reported,
corticosteroids were most frequently
prescribed (45/55) followed by
mycophenolate (17/55); overall, 47%
(26/55) of patients taking antifibrotics or
immunosuppressants died. Significantly
more patients with ILD received oral
corticosteroids in the hospital than patients
without ILD (27.8% vs. 9.9%; P, 0.001),
but there was no difference in outcome
between those receiving corticosteroids
(48.9% mortality [22/55]) and those who
did not (48.7% mortality [57/117]).
Discussion
Determining the risk of poor outcome in
patients with preexisting conditions who
acquire SARS-CoV-2 infection is crucial to
determine what mitigation measures are
required in the community. Our study
shows that patients with existing interstitial
lung disease were at very high risk of death
when hospitalized with COVID-19,
especially if they have reduced prior lung
function or obesity. Most died without being
offered mechanical ventilation; in those who
were ventilated, mortality was very high.
Our observations were in keeping with
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Figure 3. (A) Effect of interstitial lung disease (ILD) on mortality after coronavirus disease (COVID-19) (propensity matched), (B) effect of obesity and ILD
(propensity matched), and (C) effect of FVC on outcome in patients with ILD only. CI =confidence interval; HR=hazard ratio; IPF= idiopathic pulmonary fibrosis.
Table 2. Outcomes by ILD
Total (n) No ILD ILD P Value
Died 483 114 (35.4) 79 (49.1) 0.013
Respiratory support 483
Unenhanced respiratory support* 254 (78.9) 136 (84.5) 0.288
Enhanced respiratory support 39 (12.1) 20 (12.4) —
Ventilation 29 (9.0) 6 (3.7) —
Length of stay for those alive, median (IQR) 290 9.0 (11.0) 10.0 (8.0) 0.725†
Definition of abbreviations: ILD= interstitial lung disease; IQR= interquartile range.
Data are shown as n (%) unless noted otherwise. All tests are chi-square except where noted.
*Standard-flow-rate oxygen supplementation not considered “enhanced” respiratory support;
continuous positive airway pressure and high-flow O2 considered enhanced respiratory support.
†Kruskal-Wallis used.
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age, comorbidities (diabetes mellitus,
ischemic heart disease, and other non-ILD
chronic pulmonary diseases), and male sex
as predictors of poor outcome in COVID-19
(9, 12). Unfortunately, the risk for patients
with ILD has not yet been quantified
because patients with uncommon diseases
often do not have their specific diagnostic
information recorded in large observational
studies or are often not accurately reported
in administrative healthcare data sets.
Despite the unknown risk of COVID-19 for
patients with ILD, many patients chose to
self-isolate, and therefore, there appeared to
be apparent “protection” from COVID-19
observed to many ILD physicians around
the world. To accurately understand the
risk of COVID-19 and inform decision-
and risk-matrices going forward, the
European ILD community undertook an
audit of hospitalized patients with ILD
between the March 1 and May 1, 2020, to
coincide with the first peak of COVID-19
within Europe. These data represent the
largest assessment of the impact of SARS-
CoV-2 infection on patients with ILD to
date. These data demonstrate that patients
with ILD are at increased risk of death after
hospitalization for COVID-19, particularly
elderly males with poor lung function and
obesity. It is notable that the risk of in-
hospital mortality from COVID-19 for
patients with ILD is particularly associated
with male sex and obesity. These risk
factors are associated both
with development of IPF and with
mortality from COVID-19 in the general
population, which may suggest synergy
between shared mechanisms of
pathogenesis (13).
The role of viral infection promoting
acute exacerbations of ILD has been
investigated for a number of years without a
definitive answer, which probably reflects
the range of viruses studied, the number
of patients needed to explore such a
hypothesis, and more broadly the challenges
studying acute exacerbations of ILD
(14–17). These data confirm that patients
with ILD are at increased risk of mortality
from COVID-19 compared with a
matched population without ILD, and
the risk is greatest for IPF consistent with
a respiratory virus inducing acute
exacerbations of ILD.
Factors associated with poor prognosis
in acute exacerbations of ILD include
pulmonary fibrosis and poor lung function
before admission and fibrotic ILDs (18–21).
The data presented here support these prior
studies demonstrating that patients with a
recorded FVC ,80% predicted before
admission had an increased mortality
compared with those with an FVC .80%.
Similarly, patients with fibrotic ILDs such
as chronic hypersensitivity pneumonitis
had mortality rates comparable with IPF
and higher than those with sarcoid or
connective tissue disease–associated ILD.
Interestingly, obese patients with ILD had a
substantially increased risk of mortality.
This may reflect use of steroids in severe
disease, although we do not favor this
hypothesis as there was no apparent
increased risk of death associated with
corticosteroid use. Obesity may be due to
limited activity in patients with ILD, a
condition that leads to progressive
reduction in exercise tolerance as it
becomes more severe (22). Alternatively,
and perhaps most intriguingly, it may lend
support to the hypothesis that severe ILD is
part of the “metabolic syndrome” (23).
This analysis also assessed respiratory
support offered to patients hospitalized with
ILD. In line with current practice and
guidelines, most patients did not receive any
ventilatory support (7, 24). Most patients
who survived did not require enhanced
respiratory support such as high-flow
oxygen, continuous positive airway
pressure, or ventilation, and of those
receiving enhanced respiratory support,
the majority died. These data continue
to support the use of supportive care in
preference to either noninvasive or invasive
mechanical ventilation except in clearly
defined cases such as predominantly
inflammatory ILD or bridging to
transplantation.
This analysis has a number of strengths.
It is the largest international, multicenter
study to assess the outcome of patients with
interstitial lung disease hospitalized with the
respiratory infection SARS-CoV-2. Merging
Table 3. Lung Function in ILD Group by Outcome
Label Total (n) Alive Died P Value
FVC, mean (SD) 147 2.7 (1.0) 2.6 (0.9) 0.372*
FVC, percentage of predicted, mean (SD) 151 82.2 (23.0) 76.8 (21.0) 0.135*
FVC, percentage of predicted 151
,80% 35 (42.7) 42 (60.9) 0.039
.80% 47 (57.3) 27 (39.1) —
FVC, percentage of predicted 151
,50% 7 (6.9) 4 (4.8) 0.070
50–80% 28 (27.7) 38 (45.8) —
80–100% 33 (32.7) 17 (20.5) —
.100% 14 (13.9) 10 (12.0) —
DLCO, mean (SD) 81 5.2 (3.4) 4.2 (1.9) 0.093*
DLCO, percentage of predicted, mean (SD) 122 56.4 (19.4) 49.6 (21.6) 0.072*
Definition of abbreviation: ILD= interstitial lung disease.
Data are shown as n (%) unless noted otherwise. All patients with ILD are shown, including those
unmatched. All tests are Welch’s two-sample t test except where noted.
*Kruskal-Wallis used.
Table 4. Use of Ventilation in Patients with ILD by Outcome
Total (n) Alive Died P Value
Respiratory support 161
Unenhanced respiratory support* 76 (92.7) 59 (74.7) 0.015
Enhanced respiratory support 5 (6.0) 15 (23) 0.005
Ventilation 1 (1.2) 5 (3.8) 0.190
Definition of abbreviation: ILD= interstitial lung disease.
Data are shown as n (%). All tests are chi-square except where noted.
*Standard-flow-rate oxygen supplementation not considered “enhanced” respiratory support;
continuous positive airway pressure and high-flow O2 considered enhanced respiratory support.
Note that a further 10 patients with ILD were ventilated but not included in the matched cohort;
of those, 6 survived.
ORIGINAL ARTICLE
1662 American Journal of Respiratory and Critical Care Medicine Volume 202 Number 12 | December 15 2020
 
of the ILD Audit data set with the ISARIC4C
CCP-UK data set enabled accurate,
contemporary propensity score matching
for a number of potential confounding
factors to assess the risk from COVID-19
disease. This enabled an assessment of the
risk to patients with ILD infected with
SARS-CoV-2, facilitating evidence-based
mitigation strategies, such as self-isolation,
for this vulnerable group of patients.
This study also has some potential
weaknesses. Because of the retrospective
nature of the data collection, recall bias
might have led to overselection of severe
cases of COVID-19 in patients with ILD;
however, this is mitigated by the large
number of centers participating in the audit.
Similarly, because only hospitalized patients
could be included, it is possible that a large
number of patients with ILD and COVID-
19 were omitted, and therefore, the risk of
COVID-19 could be overstated. However,
given the demographic associated with
ILD, we think this is unlikely. Also, the
comparator group only included patients
from the UK and some younger patients,
which could have led to residual
confounding by geographical determinants
of disease severity and treatment; however,
because 86% of the patients with ILD
were recruited from the UK, we think
this is unlikely to be a major source of
confounding. Although patients with
ILD were less likely to receive invasive
mechanical ventilation, this is more likely
due to their severe respiratory disease;
however, there was insufficient detail in the
audit data collection to match for COVID-
19 severity based on admission severity
scores or provide more granularity relating
to the nature of respiratory support received.
However, we did not observe any patterns
across the groups that were likely to have
an effect. Similarly, the propensity score
matching will have helped to address any
imbalances that are observed within the
matching variables.
The effect of obesity was assessed in
the matched population, suggesting an
increased risk in patients without ILD;
however, in contrast with prior reports (9,
25), no effect of obesity was observed in
the control population. This reflects the
limitations associated with recording
obesity using inpatient data where obesity is
not objectively measured as well as the
relatively small numbers of patients used
in the matching and the large amount of
missing data relating to weight. Therefore,
the data relating to obesity must be interpreted
accordingly, but we believe as a modifiable
risk factor it is important to highlight the
risk of obesity in patients with ILD who
might develop COVID-19. Finally, it was
not possible to evaluate specific treatment
effects, such as the use of antifibrotics,
immunosuppressants, or antiviral therapies.
The audit was undertaken in the early part
of the pandemic when hydroxychloroquine
and remdesivir were only available in the
context of clinical trials. The UK Medicine
Health Regulatory Agency did not approve
remdesivir for use in the UK until May 26,
2020, and hydroxychloroquine has been
shown to have no effect on outcome in any
circumstance of COVID-19 infection (26,
27); therefore, it is highly unlikely that the
results are confounded by antiviral therapy.
Only a proportion of patients received
antifibrotics during their admission.
Furthermore, owing to the unknown effect
of antifibrotics and concerns regarding
immunosuppression on the clinical course
of COVID-19, there is likely to be
considerable confounding owing to
indication. There are both potential benefits
(28, 29) and harms associated with
background therapy for ILD (30). With
specific reference to corticosteroids, our
analysis did not show any effect on mortality
in patients with ILD. Although the
RECOVERY (Randomised Evaluation of
COVID-19 Therapy) study demonstrated an
overall beneficial effect of dexamethasone in
patients with COVID-19, there was
considerable heterogeneity in the response
(27), and it is not clear to what extent steroid
choice, steroid dosing, steroid duration, or
pre–COVID-19 steroid therapy impact on
outcome. However, it is reassuring from a
safety perspective that there was no obvious
signal suggesting harms associated with
background therapy for ILD in patients with
COVID-19, although further study to evaluate
the consequence of antifibrotic and
immunomodulatory therapy in ILD are
needed.
Conclusions
These data demonstrate that patients with
ILD, particularly those with fibrotic ILD, are
at higher risk of mortality from COVID-19
than patients without ILD. Furthermore,
the risk is heightened in elderly males and
those with obesity or poor lung function,
and we would recommend dietary advice
in overweight patients. We also propose
that patients with ILD, particularly severe
fibrotic ILD, continue to be regarded as high
risk of mortality fromCOVID-19 and follow
national self-isolation guidelines for
vulnerable individuals and be prioritized
for SARS-CoV-2 vaccination at such time as
it becomes available. Finally, we believe
these data demonstrate the importance of
international collaboration to collect data to
understand the consequences of emerging
threats to patients with ILD. n
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